Discovery and development of new antibiotics: the problem of antibiotic resistance.
作者信息
Silver L L, Bostian K A
机构信息
Department of Microbiology and Molecular Genetics, Merck Research Laboratory, Rahway, New Jersey 07065-0900.
出版信息
Antimicrob Agents Chemother. 1993 Mar;37(3):377-83. doi: 10.1128/AAC.37.3.377.
Abstract
摘要
相似文献
1
Discovery and development of new antibiotics: the problem of antibiotic resistance.
Antimicrob Agents Chemother. 1993 Mar;37(3):377-83. doi: 10.1128/AAC.37.3.377.
2
Using computers to ESKAPE the antibiotic resistance crisis.
Drug Discov Today. 2022 Feb;27(2):456-470. doi: 10.1016/j.drudis.2021.10.005. Epub 2021 Oct 21.
3
Antibiotic resistance: what, why, where, when and how?
Br Med Bull. 2015;116:105-13. doi: 10.1093/bmb/ldv041. Epub 2015 Oct 21.
4
Nano-technology for targeted drug delivery to combat antibiotic resistance.
Expert Opin Drug Deliv. 2012 Nov;9(11):1325-32. doi: 10.1517/17425247.2012.717927. Epub 2012 Aug 28.
5
The impact of bacterial genomics on antibacterial discovery.
Adv Exp Med Biol. 1998;456:183-95. doi: 10.1007/978-1-4615-4897-3_10.
6
[Prevention of resistance to antibiotics. A complex problem].
Presse Med. 1998 Jun;27 Suppl 3:3.
7
Biofilms: Microbial Shelters Against Antibiotics.
Microb Drug Resist. 2017 Mar;23(2):147-156. doi: 10.1089/mdr.2016.0087. Epub 2016 May 23.
8
Exploiting current understanding of antibiotic action for discovery of new drugs.
Symp Ser Soc Appl Microbiol. 2002(31):4S-15S.
9
[Antibiotics: new mechanisms of resistance transfer].
Antibiot Khimioter. 1998;43(6):3-6.
10
Children as agents of change in combatting antibiotic resistance.
J Health Serv Res Policy. 2017 Oct;22(4):258-260. doi: 10.1177/1355819617701512. Epub 2017 Mar 27.
引用本文的文献
1
Targeting the G-quadruplex as a novel strategy for developing antibiotics against hypervirulent drug-resistant Staphylococcus aureus.
J Biomed Sci. 2025 Feb 5;32(1):15. doi: 10.1186/s12929-024-01109-3.
2
The fall of the mycobacterial cell wall: interrogating peptidoglycan synthesis for novel anti-TB agents.
PeerJ. 2024 Nov 14;12:e18404. doi: 10.7717/peerj.18404. eCollection 2024.
3
High-Throughput Mining of Novel Compounds from Known Microbes: A Boost to Natural Product Screening.
Molecules. 2024 Jul 8;29(13):3237. doi: 10.3390/molecules29133237.
4
Integrating bacterial molecular genetics with chemical biology for renewed antibacterial drug discovery.
Biochem J. 2024 Jul 3;481(13):839-864. doi: 10.1042/BCJ20220062.
5
Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.
EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024.
6
Planning and development of an antimicrobial stewardship program in penitentiary facilities: strategies to optimize therapeutic prescribing and reduce the incidence of antibiotic resistance.
Front Public Health. 2023 Oct 25;11:1233522. doi: 10.3389/fpubh.2023.1233522. eCollection 2023.
7
Total Synthesis and Biological Investigation of Mindapyrroles A and B.
ChemMedChem. 2023 Sep 15;18(18):e202300235. doi: 10.1002/cmdc.202300235. Epub 2023 Jul 20.
8
Evaluation of synthesized biosurfactants as promising corrosion inhibitors and alternative antibacterial and antidermatophytes agents.
Sci Rep. 2023 Feb 14;13(1):2585. doi: 10.1038/s41598-023-29715-5.
9
Effects of antibiotics on bacterial cell morphology and their physiological origins.
Biochem Soc Trans. 2022 Oct 31;50(5):1269-1279. doi: 10.1042/BST20210894.
10
Antibiotic treatments to mothers during the perinatal period leaving hidden trouble on infants.
Eur J Pediatr. 2022 Sep;181(9):3459-3471. doi: 10.1007/s00431-022-04516-6. Epub 2022 Jun 10.
本文引用的文献
1
Serious infection in an adult due to penicillin-tolerant group B streptococcus.
Arch Intern Med. 1981 Nov;141(12):1714-5.
2
Antimicrobial and beta-lactamase inhibitory activities of carpetimycins A and B, new carbapenem antibiotics.
Antimicrob Agents Chemother. 1982 Apr;21(4):536-44. doi: 10.1128/AAC.21.4.536.
3
Nucleotide sequence of dihydrofolate reductase genes from trimethoprim-resistant mutants of Escherichia coli. Evidence that dihydrofolate reductase interacts with another essential gene product.
Mol Gen Genet. 1982;187(1):72-8. doi: 10.1007/BF00384386.
4
Transport of the lipophilic analog minocycline differs from that of tetracycline in susceptible and resistant Escherichia coli strains.
Antimicrob Agents Chemother. 1982 Nov;22(5):791-9. doi: 10.1128/AAC.22.5.791.
5
In vitro activity of fludalanine combined with pentizidone compared with those of other agents.
Antimicrob Agents Chemother. 1984 May;25(5):612-7. doi: 10.1128/AAC.25.5.612.
6
Quantitative structure-activity relationships of 6-anilinouracils as inhibitors of Bacillus subtilis DNA polymerase III.
J Med Chem. 1984 Feb;27(2):181-5. doi: 10.1021/jm00368a013.
7
[Prevalence and dispersion of plasmids conferring fosfomycin resistance in enterobacteria].
Pathol Biol (Paris). 1984 Sep;32(7):755-8.
8
Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12.
J Bacteriol. 1972 Jun;110(3):935-44. doi: 10.1128/jb.110.3.935-944.1972.
9
Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression--a review.
J Antimicrob Chemother. 1985 Jul;16 Suppl A:63-90. doi: 10.1093/jac/16.suppl_a.63.
10
Contribution of two different mechanisms to erythromycin resistance in Escherichia coli.
Antimicrob Agents Chemother. 1986 Nov;30(5):694-700. doi: 10.1128/AAC.30.5.694.
Zotero 插件